文献速递白血病淋巴瘤

儿童及青年T细胞急性淋巴细胞白血病诱导失败临床基因组图谱

The Clinicogenomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic Leukemia.
PubMed 文献 · J Clin Oncol · 2023-04-25

该研究基于UKALL2003和UKALL2011两项跨国随机试验,分析T细胞急性淋巴细胞白血病诱导失败(IF)病例。IF发生率为10.3%,与年龄增长显著相关,16岁及以上患者中达20%。IF患者5年总生存率为52.1%,而缓解患者为90.2%(P < .001)。即使UKALL2011增加奈拉滨化疗并联合造血干细胞移植,结局仍未改善。

要点

  • T-ALL诱导失败发生率为10.3%,16岁及以上患者中达20%。
  • IF患者5年OS为52.1%,缓解患者为90.2%(P < .001)。
  • 巩固治疗结束时持续分子残留病者5年OS为14.3%,无残留病者为68.5%。

核心结论

  • T-ALL诱导失败在当前治疗下结局仍差。
  • 缺乏统一遗传驱动因素提示急需替代方法,尤其免疫治疗。

研究设计与样本

  • 研究UKALL2003和UKALL2011两项连续跨国随机试验中所有T-ALL诱导失败病例,以定义危险因素、治疗和结局。
  • 进行多组学分析以刻画基因组图谱。

主要发现

  • IF发生率为10.3%,与年龄增长显著相关,16岁及以上患者中发生率为20%。
  • IF患者5年OS为52.1%,缓解患者为90.2%(P < .001)。
  • 尽管UKALL2011增加奈拉滨为基础的化疗并联合造血干细胞移植巩固,结局无改善。
  • 巩固治疗结束时持续分子残留病导致结局显著更差(5年OS,14.3% vs 68.5%;HR,4.10;95% CI,1.35至12.45;P = .0071)。
  • 基因组分析显示异质性,25种不同起始病变汇聚于10个亚型定义基因;TAL1非编码病变丰富,与极差结局相关(5年OS,12.5%)。

关键数值与推荐

  • IF发生率为10.3%,16岁及以上患者中为20%。
  • IF患者5年OS为52.1%,缓解患者为90.2%(P < .001)。
  • 巩固治疗结束时持续分子残留病者5年OS为14.3%,无持续分子残留病者为68.5%(HR,4.10;95% CI,1.35至12.45;P = .0071)。
  • TAL1非编码病变者5年OS为12.5%。
  • TAL1病变联合MYC和RAS通路突变者5年OS为23.1%,无此联合者为86.4%(HR,6.84;95% CI,2.78至16.78;P < .0001)。

临床怎么用

  • 作者认为,TAL1病变联合MYC和RAS通路突变识别出的极可能常规治疗失败的患者应考虑实验性药物。
  • 作者认为,缺乏统一遗传驱动因素提示急需替代方法,尤其免疫治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Failure to respond to induction chemotherapy portends a poor outcome in childhood acute lymphoblastic leukemia (ALL) and is more frequent in T-cell ALL (T-ALL) than B-cell ALL. We aimed to address the limited understanding of clinical and genetic factors that influence outcome in a cohort of patients with T-ALL induction failure (IF). METHODS: We studied all cases of T-ALL IF on two consecutive multinational randomized trials, UKALL2003 and UKALL2011, to define risk factors, treatment, and outcomes. We performed multiomic profiling to characterize the genomic landscape. RESULTS: IF occurred in 10.3% of cases and was significantly associated with increasing age, occurring in 20% of patients age 16 years and older. Five-year overall survival (OS) rates were 52.1% in IF and 90.2% in responsive patients (P < .001). Despite increased use of nelarabine-based chemotherapy consolidated by hematopoietic stem-cell transplant in UKALL2011, there was no improvement in outcome. Persistent end-of-consolidation molecular residual disease resulted in a significantly worse outcome (5-year OS, 14.3% v 68.5%; HR, 4.10; 95% CI, 1.35 to 12.45; P = .0071). Genomic profiling revealed a heterogeneous picture with 25 different initiating lesions converging on 10 subtype-defining genes. There was a remarkable abundance of TAL1 noncoding lesions, associated with a dismal outcome (5-year OS, 12.5%). Combining TAL1 lesions with mutations in the MYC and RAS pathways produces a genetic stratifier that identifies patients highly likely to fail conventional therapy (5-year OS, 23.1% v 86.4%; HR, 6.84; 95% CI, 2.78 to 16.78; P < .0001) and who should therefore be considered for experimental agents. CONCLUSION: The outcome of IF in T-ALL remains poor with current therapy. The lack of a unifying genetic driver suggests alternative approaches, particularly using immunotherapy, are urgently needed.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. O'Connor D, Demeulemeester J, Conde L, et al. The Clinicogenomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic Leukemia. J Clin Oncol. 2023. PMID: 37098241. doi:10.1200/JCO.22.02734

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。